Experimental Ebola Vaccine to be Used in DRC Outbreak

As the virus spreads in Democratic Republic of Congo, the World Health Organization is preparing to immunize people as soon as this week.

Written byKerry Grens
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

Sierra Leone, 2015ISTOCK, HARRY1978The World Health Organization, the government of Democratic Republic of Congo, and Merck have agreed to use Merck’s unapproved Ebola vaccine as an outbreak of the virus expands in DRC.

“The cold chain is on standby, the stockpile is on standby, the teams have been put on standby including up to 40 people that conducted the initial ring vaccination trial in Guinea,” Peter Salama, the World Health Organization’s (WHO) deputy director-general of emergency preparedness and response, said during a United Nations briefing on Friday (May 11), according to Reuters. The Guinea field trial in 2016 found the vaccine to be 100 percent effective at preventing infection among the 6,000 people who received it.

So far this spring, 19 people have died of Ebola in DRC. The outbreak is in a remote part of the country, where delivering the vaccine will be a challenge because it must be kept frozen. According to STAT, the cold-chain equipment ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • kerry grens

    Kerry served as The Scientist’s news director until 2021. Before joining The Scientist in 2013, she was a stringer for Reuters Health, the senior health and science reporter at WHYY in Philadelphia, and the health and science reporter at New Hampshire Public Radio. Kerry got her start in journalism as a AAAS Mass Media fellow at KUNC in Colorado. She has a master’s in biological sciences from Stanford University and a biology degree from Loyola University Chicago.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies